Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| THYROSCOPE INC. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This randomized controlled study aims to investigate the effects of using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis. The study intends to evaluate how the use of the app affects disease progression, quality of life, and health-related behaviors associated with the disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| app user group | Experimental | The participants in this group start using wearable devices to monitor their heart rate and a mobile app to assist with the management of hyperthyroidism after being diagnosed and beginning treatment with anti-thyroid medication. |
|
| non-user group | No Intervention | The participants in this group begin treatment with anti-thyroid medication after being diagnosed with thyrotoxicosis, but they do not use the wearable devices or mobile app used in this study. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Using a mobile app that integrates with wearable devices | Other | Using a mobile app that integrates with wearable devices to monitor heart rate, check self-reported symptoms, provide disease-related information, and set medication reminders for patients with thyrotoxicosis. |
| Measure | Description | Time Frame |
|---|---|---|
| Scores of quality of life assessed by SF-36 survey | Scores of quality of life assessed by SF-36 survey | baseline (at enrollment) |
| Scores of quality of life assessed by SF-36 survey | Scores of quality of life assessed by SF-36 survey | 6 weeks after baseline |
| Scores of quality of life assessed by SF-36 survey | Scores of quality of life assessed by SF-36 survey | 10 weeks after baseline |
| Scores of quality of life assessed by SF-36 survey | Scores of quality of life assessed by SF-36 survey | 14 weeks after baseline |
| antithyroidal drug compliance | Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication. | 6 weeks after baseline |
| antithyroidal drug compliance | Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication. | 10 weeks after baseline |
| antithyroidal drug compliance | Medication adherence assessed by directly counting the remaining pills after taking the prescribed medication. | 14 weeks after baseline |
| Knowledge about hyperthyroidism |
| Measure | Description | Time Frame |
|---|---|---|
| free T4 | serum free T4 concentration | baseline |
| free T4 | serum free T4 concentration | 6 weeks after baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jae Hoon Moon, MD | Contact | +82-31-787-7068 | jaemoon76@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Bundang Hospital | Recruiting | Seongnam-si | Gyeonggi-do | 13620 | South Korea |
Not provided
| ID | Term |
|---|---|
| D006980 | Hyperthyroidism |
| ID | Term |
|---|---|
| D013959 | Thyroid Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000076251 | Wearable Electronic Devices |
| ID | Term |
|---|---|
| D055615 | Electrical Equipment and Supplies |
| D004864 | Equipment and Supplies |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A score measured through a test designed to assess the knowledge level about Graves' disease |
| 14 weeks after baseline |
| free T4 | serum free T4 concentration | 10 weeks after baseline |
| free T4 | serum free T4 concentration | 14 weeks after baseline |
| free T3 | serum free T3 concentration | baseline |
| free T3 | serum free T3 concentration | 6 weeks after baseline |
| free T3 | serum free T3 concentration | 10 weeks after baseline |
| free T3 | serum free T3 concentration | 14 weeks after baseline |
| TSH | serum free TSH concentration | baseline |
| TSH | serum free TSH concentration | 6 weeks after baseline |
| TSH | serum free TSH concentration | 10 weeks after baseline |
| TSH | serum free TSH concentration | 14 weeks after baseline |